357 related articles for article (PubMed ID: 26940802)
1. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
[TBL] [Abstract][Full Text] [Related]
2. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347
[TBL] [Abstract][Full Text] [Related]
4. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines.
Colombo GL; Colangeli V; Di Biagio A; Di Matteo S; Viscoli C; Viale P
Clinicoecon Outcomes Res; 2011; 3():197-205. PubMed ID: 22163167
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China.
Zang X; Tang H; Min JE; Gu D; Montaner JS; Wu Z; Nosyk B
PLoS One; 2016; 11(11):e0167308. PubMed ID: 27893864
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
[TBL] [Abstract][Full Text] [Related]
13. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
[TBL] [Abstract][Full Text] [Related]
15. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
[TBL] [Abstract][Full Text] [Related]
17. The cost effectiveness of combination antiretroviral therapy for HIV disease.
Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.
Elbasha EE; Szucs T; Chaudhary MA; Kumar RN; Roediger A; Cook JR; Opravil M
HIV Clin Trials; 2009; 10(4):233-53. PubMed ID: 19723611
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy.
Hornberger J; Green J; Wintfeld N; Cavassini M; Rockstroh J; Giuliani G; De Carli C; Lazzarin A
HIV Clin Trials; 2005; 6(2):92-102. PubMed ID: 15983893
[TBL] [Abstract][Full Text] [Related]
20. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
